Health and Healthcare

Are BioSpecifics Shareholders Getting Enough in the Endo Buyout?

AaronAmat / Getty Images

News that Endo International PLC (NASDAQ: ENDP) would acquire BioSpecifics Technologies Corp. (NASDAQ: BSTC) sent shares of the latter rocketing higher on Monday. Both boards of directors have unanimously approved the merger agreement.

The price tag on this acquisition is $88.50 per share, or about $658 million in aggregate. That is roughly $540 million in enterprise value net of cash on hand. Endo is commencing an all-cash tender offer at the aforementioned price and is funding it with cash on hand.

Are BioSpecifics shareholders actually getting a good deal?

Excluding Monday’s move, BioSpecifics stock was up just 7% year to date, barely lagging the S&P 500. In the past 52 weeks, the share price was up closer to 24%, beating the broad markets.

This transaction implies premiums of 47.2% and 49.9% from the 50-day and 200-day moving averages of $60.11 and $59.03, respectively.

Note that this stock broke the $70 price level last year, but obviously this year has been much more difficult. Either way, the $88.50 price tag seems to imply a reasonable premium, considering the stock’s recent history.

What Endo gets from this deal is a company that pioneered the development of collagenase-based therapies. BioSpecifics has an injectable collagenase portfolio, consisting of Xiaflex to treat the vast number of diseases and medical conditions caused by the excess accumulation of collagen and Qwo for the treatment of cellulite

Look for this deal to close sometime in the fourth quarter of this year.

BioSpecifics stock traded up about 44% to $88.18 on Monday, in a 52-week range of $42.00 to $88.25. The consensus price target is $100.00.

Endo stock was up roughly 6%, at $5.28 in a 52-week range of $2.08 to $7.10. The consensus analyst target is $5.25.

Take Charge of Your Retirement In Just A Few Minutes (Sponsor)

Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.

Here’s how it works:

  1. Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
  2. Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
  3. Choose Your  Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.

Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!

 

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.